EBEmir Bicakcic

Emir Bicakcic

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Emir Bicakcic has a total of 12 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Predictive Value of Inflammatory Indexes as Biomarkers of Neoadjuvant Chemotherapy Response in Locally Advanced Breast Cancer

    by Vedad Dedic, Timur Ceric, Sadat Pusina, Mirhan Salibasic, Nejra Selak, Emir Bicakcic, Nedim Katica

    Background: Breast cancer remains the most common cancer in women worldwide. Treatment has evolved into multimodal approaches, with pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC) serving as a key prognostic marker. The aim of this study was to evaluate the value of inflammatory markers in predicting pCR to NAC in breast cancer. Methods: This cross-sectional study of 74 patients with breast cancer who underwent NAC followed by surgery included demographic, tumor, and immune-inflammatory marker data. Receiver operating characteristic curve analysis and the Youden index were used to determine optimal cutoff values. Univariate and multivariate logistic regression assessed associations between markers and pCR, adjusting for tumor stage, human epidermal growth factor receptor 2 (HER2), and estrogen receptor (ER) status. Results: Our multivariate analysis identified the pan-immune-inflammation value (PIV), HER2 status, and ER status as significant independent predictors of pCR. PIV (OR, 4.28; 95% CI, 1.59–16.88) remained significant among inflammatory markers, while the neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), and platelet-to-lymphocyte ratio (PLR) did not. HER2-positive (OR, 7.45; 95% CI, 2.30–24.15) and hormone receptor (HR)–negative (OR, 7.02; 95% CI, 2.63–18.70) statuses were also strongly associated with pCR. Conclusion: PIV is a robust predictor of pCR in patients with breast cancer receiving NAC, offering a comprehensive reflection of the immune-inflammatory state. Incorporating PIV with tumor-specific markers (e.g., receptor status, Ki-67, grade) may enhance treatment stratification. Further validation in diverse cohorts is warranted.


  • Open Access

    Rectal Signet-Ring Cell Adenocarcinoma with Cutaneous Metastases: A Rare Form of Colorectal Cancer - A Case Report

    by Mirhan Salibasic, Ilma Turkovic, Meleka Rastic, Minela Zrno, Sadat Pusina, Edin Hodzic, Emir Bicakcic, Vedad Dedic, Edin Medjedovic

    Introduction. Primary rectal signet-ring cell adenocarcinoma represents one of the rarest subtypes (1.39% of cases) and is associated with poor prognosis. Case report. We report the case of a 31-year-old female patient with rectal signet-ring cell adenocarcinoma who developed cutaneous metastases. Conclusion. Despite early initiation of treatment, survival in patients with rectal signet-ring cell adenocarcinoma remains poor. Key words: Rectal Neoplasms, Adenocarcinomas, Signet-Ring Cell, Skin Neoplasms.

  • Objective Response Rate According to Response Evaluation Criteria in Solid Tumors in Patients with Metastatic Colorectal Cancer and Their Influence on Progression Free Survival and Overall Survival

    by Mirhan Salibasic, Sadat Pusina, Edin Hodzic, Emir Bicakcic, Advan Dizdarevic

    Introduction. Colon cancer is one of the most common forms of cancer, affecting both sexes equally. The objective tumor response rate (ORR) is an important parameter that proves the effectiveness of treatment in oncology; one of the ways to evaluate ORR is the response evaluation criteria in solid tumors Response evaluation criteria in solid tumors (RECIST). The aim of the research is to determine and compare the impact of the objective response rate in patients with metastatic colorectal cancer and the impact on overall survival (OS) and progression-free survival (PFS). Methods. The work is based on a retrospective (2014-2020) clinical study, with follow-up of patients over a period of 5 years. The research included a total of n=101 patients diagnosed with colorectal cancer (stages II and III according to the American Joint Committee of Cancer -AJCC). Research included n=101 patients, 52% male, 48% female. The youngest patient is 18 years old, and the oldest patient is 80 years old. Results. The average age is 59.69 years. The obtained data show that the largest percentage of Colorectal Cancer-CRC patients are in the third age. Adenocarcinoma is the most common pathohistological verification of colon cancer (77.23%). Overall survival and progression-free time in relation to objective response to therapy (ORR) according to RECIST criteria did not show statistical significance. One patient had a complete response (CR) to therapy, six patients (5.94%) had a partial response (PR) to therapy. Stable disease (SD) was verified in 32.67%, and disease progression (PD) was confirmed in 60.39% of subjects. Conclusion. The extent of objective response to therapy has no influence on overall survival and survival without disease progression in patients with metastatic colorectal disease. Key words: colorectal, cancer, response evaluation criteria in solid tumors.